Tempus AI, Inc. has announced the national launch of its OneOme pharmacogenomics (PGx) testing solution, designed to deliver advanced genetic insights that optimize medication safety, dosing, and toxicity risk assessment. This strategic expansion enhances the company's precision medicine capabilities by addressing how a patient's body processes treatments.

The introduction of the OneOme solution follows Tempus AI's acquisition of OneOme in November 2025. By fully integrating these capabilities, Tempus AI aims to bridge the critical gap between genomic tumor profiling and the practical application of treatment data.

Precision Medicine Portfolio Expansion

The integration of OneOme allows Tempus AI to offer a more comprehensive suite of diagnostic tools. The pharmacogenomics testing provides clinicians with actionable data to tailor treatments based on individual genetic profiles.

Key Features of the Launch

• Optimization: Improves medication safety and dosing accuracy.
• Risk Assessment: Evaluates toxicity risks associated with treatments.
• Integration: Bridges genomic profiling with treatment processing data.

The launch represents a significant step in Tempus AI's mission to leverage artificial intelligence in advancing patient care and precision medicine.

Tempus AI Inc. (NASDAQ: TEM) shares fell nearly 6% on Monday, extending year-to-date losses to 16%, following the announcement of a $1.5 billion all-stock acquisition of Personalis, Inc. (NASDAQ: PSNL). The deal aims to expand Tempus's oncology platform but has sparked concerns regarding shareholder dilution ahead of its earnings report on July 30.

Despite the recent selloff, Tempus remains the fourth-largest holding in the ARK Innovation ETF (BATS: ARKK), accounting for roughly 5.5% of the portfolio. Wall Street analysts maintain a bullish outlook, with consensus estimates from 19 analysts setting an average price target of $66.50, implying approximately 37% upside from current levels. Recent ratings from Guggenheim, Freedom Capital Markets, and Needham average $66.33, indicating that expectations remain largely unchanged despite the pullback.

Technically, the stock's momentum has deteriorated. Tempus is trading below its eight-day, 20-day, and 50-day simple moving averages, signaling negative short- and intermediate-term trends. The Moving Average Convergence Divergence (MACD) shows a bearish crossover, and the Relative Strength Index (RSI) has slipped to around 40, suggesting fading buying momentum without yet reaching oversold territory.

The divergence between fundamental support and technical weakness presents a dilemma for investors. While the Personalis acquisition strengthens Tempus's leadership in AI-powered precision oncology, the market's reaction focuses on the deal's structure and timing. The upcoming earnings report on July 30 may serve as a critical catalyst, potentially validating analyst optimism if the company demonstrates a clear path to integration and margin improvement.